Clinical Trials Logo
  1. Home
  2. Diabetes Mellitus, Type 2
  3. NCT01565096

Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy

Diabetes Mellitus Type II Clinical Trial

Official title:
Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy

Clinical Trial Summary

The aim of this pilot-study is to investigate the effect of Vildagliptin in comparison to glimepiride on beta cell function and the cardiovascular risk profile in patients previously treated with Metformin monotherapy.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01565096
Study type Interventional
Source ikfe-CRO GmbH
Contact Thomas Forst, Prof. Dr.
Phone +49 6131 576 36 16
Email thomasf@ikfe.de
Status Recruiting
Phase Phase 4
Start date November 2011
View Details
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT02261545 - The Effect of n-3 Fatty Acid Supplementation on Serum Levels, and Gene Expression of type2 Diabetes Patient Phase 4
Completed NCT02028091 - Diabetes Mellitus - A Diagnosis Trial by Means of Non Invasive Measurements N/A
Completed NCT01684813 - VERifynow in DIabetes Non-responsiveness: a Study on Switching From Clopidogrel to Prasugrel Phase 4
Completed NCT01252524 - Effect of Calcium Polycarbophil on Type II Diabetes Mellitus Control: a Randomized Double-blind Study N/A
Recruiting NCT01311401 - Predictors of Future Type 2 Diabetes Mellitus in Circassians Minority in Israel N/A
Completed NCT00563225 - 20 Week Bridging Study in Type II DM Phase 3
Completed NCT00151697 - LANN-study: Lantus, Amaryl, Novorapid, Novomix Study Phase 3
Withdrawn NCT01453751 - Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered in Patients With Type II Diabetes N/A
Not yet recruiting NCT01775059 - Collection of Performance Data From the Integrated Sensor and Infusion Set. TRIAL 4 N/A
Completed NCT01281098 - Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation and PRP (Monotherapy) in the Treatment With High Risk PDR. Phase 2
Completed NCT01669473 - A Primary Care, EHR- Based Strategy to Promote Safe and Appropriate Drug Use N/A
Completed NCT02036372 - Perioperative Insulin, GIK or GLP-1 Treatment in Diabetes Mellitus N/A
Completed NCT03258840 - EPA Supplementation on Vascular Inflammation, and Gene Expression of PON2 in Patients With Type II Diabetes Mellitus N/A
Active, not recruiting NCT01386801 - Multicenter Research Study to Build a Repository to Study Chronic Diseases in Indiana N/A
Completed NCT02144948 - Investigation of the Effect of E.-Coli-Nissle as Supporting Therapy to Standard Care of Diabetes Mellitus Type II Phase 3